EUVIMEDEUVIMED entdecken
Multizentrische Studie

Long‐term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma

Winifred M Lo, Epameinondas Dogeas, Mark S Etherington, Cristina Ferrone, Martina Nebbia, Sean Cleary, Ron Pery, Jennifer L Steel, Samer T Tohme, David A Geller

Journal of Surgical Oncology · 2024

DOI: 10.1002/jso.27539 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Winifred M Lo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Anus Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Victor and Anna Mae Beghini Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives There is limited research on management of metastatic anal canal squamous cell carcinoma (SCC) to the liver. This study aimed to describe outcomes for patients undergoing liver resection of anal SCC metastases.

Methods

A multicenter, retrospective cohort study was conducted by three tertiary‐referral centers. Patients undergoing liver surgery between 2008 and 2022 were included. Cox regression analysis was performed to evaluate predictors of recurrence and survival and Kaplan–Meier analysis was performed for 1‐, 3‐, and 5‐year survival.

Results

Twenty‐one patients underwent liver resection and/or ablation. None were HIV positive and 24% had known HPV infection. 20/21(95%) patients had undergone Nigro protocol for management of the primary tumor with 12/21 (57%) patients experiencing complete response. 4/21 (19%) patients had synchronous liver metastases at time of diagnosis. Median tumor size was 5.0 cm and median tumor number was one. At analysis, 52% remained alive. Median overall survival was 32.2 months. 5‐year overall survival was 50%. Median recurrence‐free survival was 7.7 months and 5‐year recurrence‐free survival was 30%. Need for salvage abdominoperineal resection was negatively associated with recurrence‐free survival. The most common site of recurrence was the liver.

Conclusions

Liver resection for metastatic anal SCC can be beneficial for appropriately selected patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellAnus NeoplasmsHumansRetrospective StudiesCombined Modality TherapyKaplan-Meier EstimateLiverNeoplasm Recurrence, Local

Stichwörter der Autor:innen

anal cancerliver surgerymetastatic

Autor:innen und Institutionen

  • Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.

Förderung

  • Victor and Anna Mae Beghini Charitable Foundation

Zitieren

APA

Lo, W. M., Dogeas, E., Etherington, M. S., Ferrone, C., Nebbia, M., Cleary, S., Pery, R., Steel, J. L., Tohme, S. T., & Geller, D. A. (2024). Long‐term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27539

Vancouver

Lo WM, Dogeas E, Etherington MS, Ferrone C, Nebbia M, Cleary S, et al. Long‐term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27539

BibTeX
@article{Lo2024,
  author = {Lo, Winifred M and Dogeas, Epameinondas and Etherington, Mark S and Ferrone, Cristina and Nebbia, Martina and Cleary, Sean and Pery, Ron and Steel, Jennifer L and Tohme, Samer T and Geller, David A},
  title = {Long‐term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1002/jso.27539}
}
Kostenlos starten →